Salud financiera de hoja de balance de United Therapeutics
Salud financiera controles de criterios 5/6
United Therapeutics tiene un patrimonio de accionistas total de $6.0B y una deuda total de $700.0M, lo que sitúa su ratio deuda-patrimonio en 11.7%. Sus activos y pasivos totales son $7.2B y $1.2B respectivamente. El BAIT de United Therapeutics es de $1.2B, por lo que su ratio de cobertura de intereses es de -11.5. Tiene efectivo e inversiones a corto plazo que ascienden a $3.0B.
Información clave
11.7%
Ratio deuda-patrimonio
US$700.00m
Deuda
| Ratio de cobertura de intereses | -9.8x |
| Efectivo | US$2.99b |
| Patrimonio | US$5.98b |
| Total pasivo | US$1.18b |
| Activos totales | US$7.17b |
Actualizaciones recientes sobre salud financiera
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20Recent updates
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($3.6B) de UTHR superan a sus pasivos a corto plazo ($804.4M).
Pasivo a largo plazo: Los activos a corto plazo de UTHR ($3.6B) superan a sus pasivos a largo plazo ($377.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: UTHR tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de UTHR ha crecido de 9% a 11.7% en los últimos 5 años.
Cobertura de la deuda: La deuda de UTHR está bien cubierta por el flujo de caja operativo (139.7%).
Cobertura de intereses: UTHR gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.